Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Jan 6;386(1):24-34.
doi: 10.1056/NEJMoa2109970.

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A Tawbi  1 , Dirk Schadendorf  1 , Evan J Lipson  1 , Paolo A Ascierto  1 , Luis Matamala  1 , Erika Castillo Gutiérrez  1 , Piotr Rutkowski  1 , Helen J Gogas  1 , Christopher D Lao  1 , Juliana Janoski De Menezes  1 , Stéphane Dalle  1 , Ana Arance  1 , Jean-Jacques Grob  1 , Shivani Srivastava  1 , Mena Abaskharoun  1 , Melissa Hamilton  1 , Sarah Keidel  1 , Katy L Simonsen  1 , Anne Marie Sobiesk  1 , Bin Li  1 , F Stephen Hodi  1 , Georgina V Long  1 ; RELATIVITY-047 Investigators
Collaborators, Affiliations
Clinical Trial

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A Tawbi et al. N Engl J Med. .

Abstract

Background: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation.

Methods: In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab and nivolumab as a fixed-dose combination as compared with nivolumab alone when administered intravenously every 4 weeks to patients with previously untreated metastatic or unresectable melanoma. The primary end point was progression-free survival as assessed by blinded independent central review.

Results: The median progression-free survival was 10.1 months (95% confidence interval [CI], 6.4 to 15.7) with relatlimab-nivolumab as compared with 4.6 months (95% CI, 3.4 to 5.6) with nivolumab (hazard ratio for progression or death, 0.75 [95% CI, 0.62 to 0.92]; P = 0.006 by the log-rank test). Progression-free survival at 12 months was 47.7% (95% CI, 41.8 to 53.2) with relatlimab-nivolumab as compared with 36.0% (95% CI, 30.5 to 41.6) with nivolumab. Progression-free survival across key subgroups favored relatlimab-nivolumab over nivolumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients in the relatlimab-nivolumab group and in 9.7% of patients in the nivolumab group.

Conclusions: The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Progression-free Survival.
Data shown include all patients who underwent randomization. Hazard ratios were estimated with a stratified Cox proportional-hazards model. P values were calculated with the use of a log-rank test stratified according to expression of lymphocyte-activation gene 3 (LAG-3) (≥1% vs. <1%), BRAF mutation status (mutant vs. wild-type), and American Joint Committee on Cancer metastasis stage (M0 or M1 with normal LDH level vs. M1 with elevated LDH level). Programmed death ligand 1 was not used for stratification because it resulted in subgroups with fewer than 10 patients. Tick marks indicate censored data.
Figure 2.
Figure 2.. Progression-free Survival, According to Subgroup.
The exploratory and descriptive analyses and proportional-hazards assumptions were not tested for the subgroup exploratory analyses, so hazard ratios should be interpreted with caution. The Eastern Cooperative Oncology Group (ECOG) performance status is assessed on a 5-point scale, with 0 indicating no performance restrictions and higher scores indicating greater disability. The tumor burden was measured by blinded independent central review. Q1 denotes the middle value between the smallest value and the median; 25% of data are below Q1. Q3 denotes the middle value between the median and the highest value; 75% of data are below Q3. LDH denotes lactate dehydrogenase, PD-L1 programmed death ligand 1, and ULN upper limit of the normal range.
Figure 3.
Figure 3.. Progression-free Survival, According to LAG-3 Expression.
Hazard ratios were estimated with an unstratified Cox proportional-hazards model.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–46. - PubMed
    1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol 2021;39:Suppl 15: 9506. abstract.
    1. Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One 2014;9(11):e109080. - PMC - PubMed
    1. Workman CJ, Cauley LS, Kim I-J, Blackman MA, Woodland DL, Vignali DAA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. J Immunol 2004;172:5450–5. - PubMed
    1. Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011;186:5173–83. - PubMed

Publication types

MeSH terms

Associated data